This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- INVEGA SUSTENNA (paliperidone palmitate 1-month), INVEGA TRINZA(paliperidone palmitate 3-month) and INVEGA HAFYERA (paliperidone palmitate 6-month) are intended as a single use intramuscular injection.1-3
- The labeling requirements specifically indicate to deliver the entire contents of the syringe upon injection.1-3
- INVEGA SUSTENNA, INVEGA TRINZA, and INVEGA HAFYERA are sterile products that do not contain preservatives.4,5
- Immediate injection of the suspension is required after removing the syringe tip cap and attaching the needle to the syringe to guarantee sterility of the product.
- If not used immediately, sterility cannot be guaranteed due to the lack of preservatives in the product.
- Administration and storage practices outside of the prescribing information are ultimately the responsibility of the end user.
PRODUCT LABELING
Please refer to local labeling for detailed information regarding dosage and administration of INVEGA SUSTENNA, INVEGA TRINZA, and INVEGA HAFYERA.
1 | Data on File. Company Core Data Sheet. Paliperidone palmitate 1-month. Version 018. Janssen Research & Development, LLC; 2022. |
2 | Data on File. Company Core Data Sheet. Paliperidone palmitate 3-month injection. Version 008. Janssen Research & Development, LLC; 2022. |
3 | Data on File. Company Core Data Sheet. Paliperidone palmitate 6-month injection. Version 003. Janssen Research & Development, LLC; 2022. |
4 | Data on File. TV-TEC-101439. Janssen Research & Development, LLC. |
5 | Data on File. TV-TEC-67824. Janssen Research & Development, LLC. |